RxDoctor Payments DataLook up a doctor →

Peter Rouvelas, MD

Interventional Cardiology · Brooklyn, NYNPI 1245243609

Payments from drug & device makers

$332,291in general payments, 2019–2025

Across 438 payments — averaging $758.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$207K
  • Johnson & Johnson$86K
  • Amarin Pharma, Inc.$27K
  • Edwards Lifesciences$7K
  • Abbott$1K
  • Amgen$524
  • plus $3K from 17 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$332,291 in reported general payments places this provider in the 85th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$168,306
Medicare patients
140
Services billed
1,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →